171 related articles for article (PubMed ID: 29932963)
1. Effectiveness of echinocandins versus fluconazole for treatment of persistent candidemia: A time-dependent analysis.
Lin KY; Chen PY; Chuang YC; Wang JT; Sun HY; Sheng WH; Chen YC; Chang SC
J Infect; 2018 Sep; 77(3):242-248. PubMed ID: 29932963
[TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness of echinocandins versus fluconazole therapy for the treatment of adult candidaemia due to Candida parapsilosis: a retrospective observational cohort study of the Mycoses Study Group (MSG-12).
Chiotos K; Vendetti N; Zaoutis TE; Baddley J; Ostrosky-Zeichner L; Pappas P; Fisher BT
J Antimicrob Chemother; 2016 Dec; 71(12):3536-3539. PubMed ID: 27494929
[TBL] [Abstract][Full Text] [Related]
3. Risk factors of mortality and comparative in-vitro efficacy of anidulafungin, caspofungin, and micafungin for candidemia.
Lee SC; Lee CW; Shih HJ; Huang SH; Chiou MJ; See LC
J Microbiol Immunol Infect; 2014 Jun; 47(3):245-53. PubMed ID: 24246191
[TBL] [Abstract][Full Text] [Related]
4. Echinocandins Compared to Fluconazole for Candidemia of a Urinary Tract Source: A Propensity Score Analysis.
Cuervo G; Garcia-Vidal C; Puig-Asensio M; Vena A; Meije Y; Fernández-Ruiz M; González-Barberá E; Blanco-Vidal MJ; Manzur A; Cardozo C; Gudiol C; Montejo JM; Pemán J; Ayats J; Aguado JM; Muñoz P; Marco F; Almirante B; Carratalà J;
Clin Infect Dis; 2017 May; 64(10):1374-1379. PubMed ID: 28329281
[TBL] [Abstract][Full Text] [Related]
5. Antimicrobial susceptibility and clinical outcomes of Candida parapsilosis bloodstream infections in a tertiary teaching hospital in Northern Taiwan.
Lin CC; Liu CP; Hsieh FC; Lee CM; Wang WS
J Microbiol Immunol Infect; 2015 Oct; 48(5):552-8. PubMed ID: 25315213
[TBL] [Abstract][Full Text] [Related]
6. Is Fluconazole or an Echinocandin the Agent of Choice for Candidemia.
Eschenauer GA; Nguyen MH; Clancy CJ
Ann Pharmacother; 2015 Sep; 49(9):1068-74. PubMed ID: 26104051
[TBL] [Abstract][Full Text] [Related]
7. Candida infections in non-neutropenic children after the neonatal period.
Hacimustafaoglu M; Celebi S
Expert Rev Anti Infect Ther; 2011 Oct; 9(10):923-40. PubMed ID: 21973304
[TBL] [Abstract][Full Text] [Related]
8. Treatment of candidemia with echinocandins: data on hospital resource use from a real world setting.
Wade RL; Chaudhari P; Campbell RS; Hays HD; Nathanson BH; Yi J; Horn D
J Med Econ; 2012; 15(6):1130-8. PubMed ID: 22788668
[TBL] [Abstract][Full Text] [Related]
9. Initial Antifungal Strategy Reduces Mortality in Critically Ill Patients With Candidemia: A Propensity Score-Adjusted Analysis of a Multicenter Study.
Garnacho-Montero J; Díaz-Martín A; Cantón-Bulnes L; Ramírez P; Sierra R; Arias-Verdú D; Rodríguez-Delgado M; Loza-Vázquez A; Rodriguez-Gomez J; Gordón M; Estella Á; García-Garmendia JL
Crit Care Med; 2018 Mar; 46(3):384-393. PubMed ID: 29189345
[TBL] [Abstract][Full Text] [Related]
10. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
11. Initial antifungal strategy does not correlate with mortality in patients with candidemia.
Murri R; Scoppettuolo G; Ventura G; Fabbiani M; Giovannenze F; Taccari F; Milozzi E; Posteraro B; Sanguinetti M; Cauda R; Fantoni M
Eur J Clin Microbiol Infect Dis; 2016 Feb; 35(2):187-93. PubMed ID: 26634352
[TBL] [Abstract][Full Text] [Related]
12. Epidemiology, risk factor, species distribution, antifungal resistance and outcome of Candidemia at a single French hospital: a 7-year study.
Tadec L; Talarmin JP; Gastinne T; Bretonnière C; Miegeville M; Le Pape P; Morio F
Mycoses; 2016 May; 59(5):296-303. PubMed ID: 26806101
[TBL] [Abstract][Full Text] [Related]
13. Fluconazole versus an echinocandin for Candida glabrata fungaemia: a retrospective cohort study.
Eschenauer GA; Carver PL; Lin SW; Klinker KP; Chen YC; Potoski BA; Shields RK; Clancy CJ; Nguyen MH; Lam SW
J Antimicrob Chemother; 2013 Apr; 68(4):922-6. PubMed ID: 23212115
[TBL] [Abstract][Full Text] [Related]
14. The Effect on mortality of fluconazole or echinocandins treatment in candidemia in internal medicine wards [corrected].
De Rosa FG; Corcione S; Filippini C; Raviolo S; Fossati L; Montrucchio C; Aldieri C; Petrolo A; Cavallo R; Di Perri G
PLoS One; 2015; 10(5):e0125149. PubMed ID: 25938486
[TBL] [Abstract][Full Text] [Related]
15. Pharmacoeconomic analysis of antifungal therapy for primary treatment of invasive candidiasis caused by Candida albicans and non-albicans Candida species.
Ou HT; Lee TY; Chen YC; Charbonneau C
BMC Infect Dis; 2017 Jul; 17(1):481. PubMed ID: 28693479
[TBL] [Abstract][Full Text] [Related]
16. Empirical and targeted therapy of candidemia with fluconazole versus echinocandins: a propensity score-derived analysis of a population-based, multicentre prospective cohort.
López-Cortés LE; Almirante B; Cuenca-Estrella M; Garnacho-Montero J; Padilla B; Puig-Asensio M; Ruiz-Camps I; Rodríguez-Baño J;
Clin Microbiol Infect; 2016 Aug; 22(8):733.e1-8. PubMed ID: 27189197
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of antifungal therapy in patients with candidaemia based on susceptibility testing results: implications for antimicrobial stewardship programmes.
Shah DN; Yau R; Weston J; Lasco TM; Salazar M; Palmer HR; Garey KW
J Antimicrob Chemother; 2011 Sep; 66(9):2146-51. PubMed ID: 21700622
[TBL] [Abstract][Full Text] [Related]
18. Candidemia in the intensive care unit: analysis of direct treatment costs and clinical outcome in patients treated with echinocandins or fluconazole.
Heimann SM; Cornely OA; Wisplinghoff H; Kochanek M; Stippel D; Padosch SA; Langebartels G; Reuter H; Reiner M; Vierzig A; Seifert H; Vehreschild MJ; Glossmann J; Franke B; Vehreschild JJ
Eur J Clin Microbiol Infect Dis; 2015 Feb; 34(2):331-8. PubMed ID: 25213718
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry.
Horn DL; Neofytos D; Anaissie EJ; Fishman JA; Steinbach WJ; Olyaei AJ; Marr KA; Pfaller MA; Chang CH; Webster KM
Clin Infect Dis; 2009 Jun; 48(12):1695-703. PubMed ID: 19441981
[TBL] [Abstract][Full Text] [Related]
20. Propensity Score Analysis of the Role of Initial Antifungal Therapy in the Outcome of Candida glabrata Bloodstream Infections.
Puig-Asensio M; Fernández-Ruiz M; Aguado JM; Merino P; Lora-Pablos D; Guinea J; Martín-Dávila P; Cuenca-Estrella M; Almirante B
Antimicrob Agents Chemother; 2016 Jun; 60(6):3291-300. PubMed ID: 26976872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
